Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Giuliani, Jacopo, Bonetti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094077/
https://www.ncbi.nlm.nih.gov/pubmed/35582308
http://dx.doi.org/10.20517/cdr.2021.14
_version_ 1784705466083835904
author Giuliani, Jacopo
Bonetti, Andrea
author_facet Giuliani, Jacopo
Bonetti, Andrea
author_sort Giuliani, Jacopo
collection PubMed
description
format Online
Article
Text
id pubmed-9094077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-90940772022-05-16 Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer Giuliani, Jacopo Bonetti, Andrea Cancer Drug Resist Commentary OAE Publishing Inc. 2021-04-27 /pmc/articles/PMC9094077/ /pubmed/35582308 http://dx.doi.org/10.20517/cdr.2021.14 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Giuliani, Jacopo
Bonetti, Andrea
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title_full Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title_fullStr Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title_full_unstemmed Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title_short Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
title_sort cost-effectiveness of osimertinib in activating epidermal growth factor receptor gene (egfr)-mutations in first-line for advanced non-small cell lung cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094077/
https://www.ncbi.nlm.nih.gov/pubmed/35582308
http://dx.doi.org/10.20517/cdr.2021.14
work_keys_str_mv AT giulianijacopo costeffectivenessofosimertinibinactivatingepidermalgrowthfactorreceptorgeneegfrmutationsinfirstlineforadvancednonsmallcelllungcancer
AT bonettiandrea costeffectivenessofosimertinibinactivatingepidermalgrowthfactorreceptorgeneegfrmutationsinfirstlineforadvancednonsmallcelllungcancer

Ejemplares similares